The results of research in recent years, a combination of new anti-tuberculosis drugs, mainly divided into nine categories: first is the rifamycin derivatives, such as rifapentine, rifabutin, benzoxazine, rifamycin; in addition, there are CGP7074, CGP27557, F22 and other long-acting anti-tuberculosis drugs; the next is the quinolone species such as ofloxacin, levofloxacin, ciprofloxacin, sparfloxacin, mo Secondly, quinolones such as ofloxacin, levofloxacin, ciprofloxacin, sparfloxacin, moxifloxacin, etc., are widely valued because they have good inhibitory and killing effects on Mycobacterium tuberculosis, are inexpensive, have less toxic side effects, and do not produce cross-resistance with other anti-tuberculosis drugs, and are a major aspect of the current research on anti-tuberculosis drugs. Fifth, β-lactams and their enzyme inhibitors, i.e., amoxicillin, clavulanic acid, etc.; Sixth, peptides, mainly tuberculosis actinomycin-N, are effective against streptomycin- or kanamycin-resistant tuberculosis bacteria, and can be used in patients with multidrug-resistant disease in combination therapy programs; Seventh, phenothiazines, mainly phenothiazines, are suitable for drug-resistant Eighth, nitroimidazoles, whose representative metronidazole, used in combination with other anti-tuberculosis drugs, not only have a killing effect on various states of tuberculosis bacteria, but also have a preventive effect on patients with latent infection; ninth, other classes, currently listed with aminosalicylic acid and isoniazid compounds Rick lung disease, now China also began to use, the effect is better, in addition, the traditional In addition, traditional Chinese herbs such as Phellodendron, Huanglian, Yinhua, Bitter ginseng and Changsan have certain inhibitory effect on Mycobacterium tuberculosis; the Miao folk medicine Brachycarpus has a very precise diagnostic and therapeutic effect on tuberculosis, etc. In short, the screening of new varieties of anti-tuberculosis drugs and their development and application are related to the health of the general public and the vital interests of patients. It is also the “focus” of common concern in the pharmaceutical industry today. As research continues, it can be concluded that TB, a disease that has had a disastrous outbreak in human history, will be controlled quickly and effectively and will not repeat the history of human suffering.